Your browser doesn't support javascript.
loading
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.
Martins-Branco, Diogo; Kassapian, Marie; Debien, Véronique; Caparica, Rafael; Eiger, Daniel; Dafni, Urania; Andriakopoulou, Charitini; El-Abed, Sarra; Ellard, Susan L; Izquierdo, Miguel; Vicente, Malou; Chumsri, Saranya; Piccart-Gebhart, Martine; Moreno-Aspitia, Alvaro; Knop, Ann Søegaard; Lombard, Janine; de Azambuja, Evandro.
Affiliation
  • Martins-Branco D; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Rue Meylemeersch, 90, Anderlecht, 1070, Brussels, Belgium.
  • Kassapian M; Frontier Science Foundation-Hellas, Athens, Greece.
  • Debien V; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Rue Meylemeersch, 90, Anderlecht, 1070, Brussels, Belgium.
  • Caparica R; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Rue Meylemeersch, 90, Anderlecht, 1070, Brussels, Belgium.
  • Eiger D; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Rue Meylemeersch, 90, Anderlecht, 1070, Brussels, Belgium.
  • Dafni U; National and Kapodistrian University of Athens & Frontier Science Foundation-Hellas, Athens, Greece.
  • Andriakopoulou C; Frontier Science Foundation-Hellas, Athens, Greece.
  • El-Abed S; Breast International Group, Brussels, Belgium.
  • Ellard SL; BC Cancer Kelowna, Kelowna, BC, Canada.
  • Izquierdo M; Novartis Pharma AG, Basel, Switzerland.
  • Vicente M; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Rue Meylemeersch, 90, Anderlecht, 1070, Brussels, Belgium.
  • Chumsri S; Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.
  • Piccart-Gebhart M; Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Moreno-Aspitia A; Jacoby Center for Breast Health, Mayo Clinic, Jacksonville, FL, USA.
  • Knop AS; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Lombard J; Calvary Mater Hospital & Australia and New Zealand Breast Cancer Trials Group (BCT-ANZ), Newcastle, Australia.
  • de Azambuja E; Academic Trials Promoting Team (ATPT), Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Rue Meylemeersch, 90, Anderlecht, 1070, Brussels, Belgium. evandro.deazambuja@hubruxelles.be.
Breast Cancer Res Treat ; 203(3): 497-509, 2024 Feb.
Article in En | MEDLINE | ID: mdl-37938495
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2024 Document type: Article Affiliation country: Belgium Country of publication: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Limits: Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2024 Document type: Article Affiliation country: Belgium Country of publication: Netherlands